IMRT Lower Limb Soft Tissue Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00188175
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : June 3, 2014
Ontario Cancer Research Network
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
Intensity-modulated radiation therapy may make wound healing problems less likely by 1)precisely shaping the region of high radiation dose to the shape of the tissue which harbours tumour cells, and 2) precisely shaping the regions of low radiation dose to the shapes of the normal tissues which are more sensitive to radiation effects.

Condition or disease Intervention/treatment Phase
Sarcoma Radiation: Intensity Modulated Radiation Therapy Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase II Study of Preoperative Intensity-Modulated Radiation Therapy For Lower Limb Soft Tissue Sarcoma
Study Start Date : May 2003
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: IMRT for lower limb soft tissue sarcoma Radiation: Intensity Modulated Radiation Therapy
Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.

Primary Outcome Measures :
  1. Major wound complications within 120 days following surgery [ Time Frame: 120 days post-op ]

Secondary Outcome Measures :
  1. Assess acute and late radiation toxicity including limb edema [ Time Frame: up to120 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven soft tissue sarcoma
  • Lesion lies between the iliac crest (hipbone) and the ankle
  • Lesion is newly diagnosed
  • Assessed by radiation oncologist and surgical oncologist

Exclusion Criteria:

  • Benign histologies
  • Histologies generally treated with chemotherapy
  • Prior or recurrent cancer, except nonmelanomatous skin cancer or carcinoma in-situ of the cervix

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00188175

Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University Health Network, Toronto
Ontario Cancer Research Network
Principal Investigator: Brian O'Sullivan, MD Princess Margaret Hospital, Canada

Responsible Party: University Health Network, Toronto Identifier: NCT00188175     History of Changes
Other Study ID Numbers: UHN REB 03-0107-C
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: June 3, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type